The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.

Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the ...

Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.

Abbott closes $21B acquisition of Exact Sciences (EXAS) at $105/share. EXAS delisted from Nasdaq on March 23, 2026, becoming ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Abbott broadens cancer diagnostics portfolio through Exact Sciences acquisition; Focus strengthens position within advanced ...

Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences ...

Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

Abbott to close the acquisition of Exact Sciences on March 23: Abbott Park, Illinois Monday, March 23, 2026, 10:00 Hrs [IST] Abbott announced that it expects to close the acquisit ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...